{"prompt": "['-', '(elevated LFTs)', 'Monitor and evaluate liver function test: AST, ALT, ALP, and TB.', '-', 'Evaluate for alternative etiologies (e.g., viral hepatitis, disease', 'Infliximab should not be used for management', 'progression, concomitant medications).', 'of immune-related hepatitis.', 'Grade 1', 'No dose modifications.', 'For Grade 1:', '(AST or ALT >ULN', 'If it worsens, then treat as Grade 2', '-', 'Continue LFT monitoring per protocol.', 'event.', 'PLEASE', 'SEE', 'and <3.0xULN and/or', 'shaded', 'TB > ULN and', 'area', 'immediately below', '<1.5xULN)', 'this section to find', 'Grade 2', 'Hold study drug/study regimen dose', 'For Grade 2:', 'guidance', 'for', 'until Grade 2 resolution to Grade 1.', '-', '(AST or', 'Regular and frequent checking of LFTs (e.g., every 1 to 2 days) until', 'management', 'of', 'ALT >3.0xULN and', 'If toxicity worsens, then treat as', 'elevations of these are improving or resolved.', '\"Hepatitis (elevated', 'Grade 3 or Grade 4.', '-', 'If no resolution to Grade 1 in 1 to 2 days, consider, as necessary,', '<5.0xULN and/or', 'LFTS)\" in HCC', 'If toxicity improves to Grade 1 or', 'discussing with study physician.', 'TB >1.5xULN and', '-', 'baseline, resume study drug/study', 'If event is persistent (>3 to 5 days) or worsens, promptly start', 'patients', '<3.0xULN)', 'regimen after completion of steroid', 'prednisone 1 to 2 mg/kg/day PO or IV equivalent.', 'taper.', '-', 'If still no improvement within 3 to 5 days despite 1 to 2 mg/kg/day of', 'prednisone PO or IV equivalent, consider additional work up and start', 'prompt treatment with IV methylprednisolone 2 to 4 mg/kg/day.', '-', 'If still no improvement within 3 to 5 days despite 2 to 4 mg/kg/day of', 'IV methylprednisolone, promptly start immunosuppressives (i.e.,', 'mycophenolate mofetil). Discuss with study physician if', 'mycophenolate mofetil is not available. Infliximab should NOT be', 'used.', 'Once the patient is improving, gradually taper steroids over >28 days', 'and consider prophylactic antibiotics, antifungals, and anti-PJP', 'treatment (refer to current NCCN guidelines for treatment of cancer-', 'related infections [Category 2B recommendation].', 'Grade 3 or 4', 'For Grade 3:', 'For Grade 3 or 4:', '-', '(Grade 3: AST or', 'For elevations in transaminases', 'Promptly initiate empiric IV methylprednisolone at 1 to 4 mg/kg/day or', 'equivalent.', 'ALT>5.0xULN and', '<8 X ULN, or elevations in bilirubin', '-', 'If still no improvement within 3 to 5 days despite 1 to 4 mg/kg/day', '<20.0xULN and/or', '<5 x ULN:', 'methylprednisolone IV or equivalent, promptly start treatment with', 'TB >3.0xULN and', 'Hold study drug/study regimen dose', 'immunosuppressive therapy (i.e., mycophenolate mofetil). Discuss with', '<10.0xULN)', 'until resolution to Grade 1 or', 'study physician if mycophenolate is not available. Infliximab should', 'baseline', 'NOT be used.', 'Resume study drug/study regimen if', '-', 'Perform hepatology consult, abdominal workup, and imaging as', '(Grade 4: AST or', 'elevations downgrade to Grade 1 or', 'appropriate.', 'baseline within 14 days and after', '-', 'ALT>20xULN and/or', 'Once the patient is improving, gradually taper steroids over >28 days', 'completion of steroid taper.', 'and consider prophylactic antibiotics, antifungals, and anti-PJP', 'TB>10xULN)', 'Permanently discontinue study', 'treatment (refer to current NCCN guidelines for treatment of cancer-', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 95 de 123']['drug/study regimen if the elevations', 'related infections [Category 2B recommendation]).', 'a', 'do not downgrade to Grade 1 or', 'baseline within 14 days', 'For elevations in transaminases >8 X ULN', 'or elevations in bilirubin >5 X ULN,', 'discontinue study drug/study regimen.', 'Permanently discontinue study drug/study', \"regimen for any case meeting Hy's law\", 'criteria (AST and/or ALT >3 X ULN +', 'bilirubin >2 X ULN without initial', 'findings of cholestasis (i.e., elevated', 'alkaline P04) and in the absence of any', 'alternative cause.b', 'For Grade 4:', 'Permanently discontinue study drug/study', 'regimen.', 'Hepatitis', 'Any Grade', 'General Guidance', 'For Any Grade:', '(elevated LFTs)', '-', 'Monitor and evaluate liver function test: AST, ALT, ALP, and TB.', '-', 'Infliximab should not be used for management', 'Evaluate for alternative etiologies (e.g., viral hepatitis, disease', 'progression, concomitant medications, worsening of liver cirrhosis [e.g.,', 'of immune-related hepatitis.', 'portal vein thrombosis]).', 'See instructions at', '-', 'For HBV+ patients: evaluate quantitative HBV viral load, quantitative', 'bottom of shaded', 'HBsAg, or HBeAg', 'THIS shaded area', '-', 'For HCV+ patients: evaluate quantitative HCV viral load', 'area', 'is guidance only for', '-', 'Consider consulting hepatologist/Infectious disease specialist regarding', 'if transaminase', 'management of', 'change/implementation in/of antiviral medications for any patient with', 'rise is', 'an elevated HBV viral load >2000 IU/ml', '\"Hepatitis (elevated', 'not isolated but', '-', 'Consider consulting hepatologist/Infectious disease specialist regarding', 'LFTs)\" in HCC', '(at any time)', 'change/implementation in/of antiviral HCV medications if HCV viral', 'patients', 'load increased by >2-fold', 'occurs in setting', '-', 'For HCV+ with HBcAB+: Evaluate for both HBV and HCV as above', 'of either', 'increasing bilirubin or signs of DILI/liver', 'No dose modifications.', 'decompensation', 'Grade 1', 'If ALT/AST elevations represents', '(Isolated AST or ALT', 'significant worsening based on', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 96 de 123']\n\n###\n\n", "completion": "END"}